Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mir1307 inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous, Intrathecal, Intravitreal
01
Overview
MIR1307 inhibitor is a research-stage antisense oligonucleotide or microRNA inhibitor designed to block the activity of miR-1307. miR-1307 is a microRNA that has been identified as a mediator of chemoresistance in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), breast cancer, and lung adenocarcinoma. By inhibiting miR-1307, these compounds aim to sensitize cancer cells to chemotherapeutic agents like FOLFIRINOX or cisplatin. The mechanism involves preventing miR-1307 from binding to its target mRNAs, such as CLIC5, thereby modulating DNA damage response pathways and other survival mechanisms in tumor cells. Currently, these inhibitors are primarily used as laboratory tools sourced from reagent vendors like Exiqon and ThermoFisher Scientific, with no specific therapeutic candidate yet in clinical development.
- Other names
- miR-1307 inhibitormiR1307 inhibitormiR 1307 inhibitormicroRNA-1307 inhibitormicroRNA1307 inhibitormicroRNA 1307 inhibitoranti-miR-1307anti-miR1307anti-miR 1307
Beyond the preview
Go deeper on mir1307 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mir1307 inhibitor.